MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jce.70364

Медицинская библиотека · Journal of cardiovascular electrophysiology · 2026

Long-Term Outcomes of Leadless Pacemaker vs. Transvenous Pacemaker in End-Stage Renal Disease.

Agarwal Siddharth, Patel Harsh P, Patil Shivaraj, Gupta Anshul, Patel Divya, Asad Zain Ul Abideen, Munir Muhammad Bilal, Sugrue Alan, Tan Nicholas Y, Munoz Freddy Del-Carpio, Cha Yong-Mei, DeSimone Christopher V, Deshmukh Abhishek

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Patients with end-stage renal disease (ESRD) undergoing dialysis have an increased risk of pacemaker-related complications due to limited vascular access and increased susceptibility to infection. Leadless pacemakers (LPMs) may mitigate these risks compared with conventional transvenous pacemakers (TPMs), but long-term comparative data in this population remain limited.

METHODS

We conducted a retrospective cohort study using the TriNetX Research Network, including adults (≥ 18 years) with ESRD on dialysis who underwent LPM or TPM implantation between May 2016 and December 2020. Propensity score matching (1:1) was performed using demographics and comorbidities. Outcomes assessed over up to 5 years included all-cause hospitalization, heart failure hospitalization, device re-intervention, device-related complications, infection-related hospitalization, pacemaker-induced cardiomyopathy, and all-cause mortality.

RESULTS

After matching, 901 patients were included in each group with well-balanced baseline characteristics. LPM implantation was associated with a significantly lower risk of device re-intervention compared with TPM (4.1% vs. 9.3%; hazard ratio [HR] 0.44; 95% confidence interval [CI] 0.28-0.69; p < 0.01). There were no significant differences between groups in all-cause hospitalization (65.5% vs. 68.3%; p = 0.22), heart failure hospitalization (26.9% vs. 30.2%; p = 0.13), all-cause mortality (37.5% vs. 35.3%; p = 0.34), device-related complications (14.5% vs. 14.3%; p = 0.94), infection-related hospitalization (1.6% vs. 2.1%; p = 0.35), or pacemaker-induced cardiomyopathy (9.0% vs. 8.6%; p = 0.66).

CONCLUSION

In a large, propensity-matched cohort of patients with ESRD on dialysis, LPMs were associated with fewer device re-interventions and comparable long-term clinical outcomes compared with TPMs.

Для цитирования: Agarwal Siddharth, Patel Harsh P, Patil Shivaraj, Gupta Anshul, Patel Divya, Asad Zain Ul Abideen, Munir Muhammad Bilal, Sugrue Alan, Tan Nicholas Y, Munoz Freddy Del-Carpio, Cha Yong-Mei, DeSimone Christopher V, Deshmukh Abhishek. Long-Term Outcomes of Leadless Pacemaker vs. Transvenous Pacemaker in End-Stage Renal Disease.. Journal of cardiovascular electrophysiology. 2026. DOI: 10.1111/jce.70364.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.